Table 2.
Intention-to-Treat | D1 | D2 | D3 | D4 | D5 | Overall |
---|---|---|---|---|---|---|
Akkasheh 2016 [32] | ||||||
Allen 2016 [59] | ||||||
Bagga 2018 [19] | ||||||
Bagga 2019 [18] | ||||||
Benton 2007 [60] | ||||||
De Lorenzo 2017 [61] | ||||||
Dickerson 2018 [73] | ||||||
Diop 2008 [62] | ||||||
Ghaderi 2019 [34] | ||||||
Ho 2021 [55] | ||||||
Hwang 2019 [35] | ||||||
Karbownik 2020 [64] | ||||||
Kato-Kataoka 2016 [37] | ||||||
Kazemi 2019 [38] | ||||||
Kelly 2017 [65] | ||||||
Nishida 2017 [43] | ||||||
Nishida 2019 [44] | ||||||
Östlund-Lagerström 2016 [67] | ||||||
Patterson 2020 [68] | ||||||
Raygan 2018 [48] | ||||||
Romijn 2017 [79] | ||||||
Sanchez 2017 [78] | ||||||
Sashihara 2013 [49] | ||||||
Sawada 2017 [50] | ||||||
Steenbergen 2015 [72] | ||||||
Xiao 2020 [56] | ||||||
Per-protocol | D1 | D2 | D3 | D4 | D5 | Overall |
Adikari 2020 [54] | ||||||
Chung 2014 [33] | ||||||
Dickerson 2014 [74] | ||||||
Eskandarzadeh 2021 [30] | ||||||
Gualtieri 2020 [63] | ||||||
Inoue 2018 [36] | ||||||
Kobayashi 2019 [39] | ||||||
Lew 2019 [40] | ||||||
Messaoudi 2011 [66] | ||||||
Mohammadi 2016 [41] | ||||||
Murata 2018 [42] | ||||||
Nishihira 2014 [45] | ||||||
Ohsawa 2018 [46] | ||||||
Papalini 2019 [20] | ||||||
Rao 2009 [75] | ||||||
Raygan 2019 [47] | ||||||
Reininghaus2020 [69] | ||||||
Roman 2018 [70] | ||||||
Romijn 2017 [79] | ||||||
Rudzki 2019 [71] | ||||||
Shinkai 2013 [58] | ||||||
Takada 2016 [52] | ||||||
Takada 2017 [51] | ||||||
Tillisch 2013 [21] | ||||||
Tran 2019 [77] | ||||||
Wang 2019 [22] | ||||||
Yamamura 2009 [53] | ||||||
Zhang 2021 [57] | ||||||
Low risk | ||||||
Some concerns | ||||||
High risk | ||||||
D1 | Randomisation process | |||||
D2 | Deviations from the intended interventions | |||||
D3 | Missing outcome data | |||||
D4 | Measurement of the outcome | |||||
D5 | Selection of the reported result |